Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.60 |
| ▸ | RAB9A | P51151 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | F10 | P00742 | 11/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10925409 | 0.83 | CYP1A2 (0.59) | CYP1A2CYP2C19RAB9ASMN1; SMN2CYP3A4 | |
| SCHEMBL3301591 | 0.79 | CYP1A2 (0.49) | CYP1A2CYP2C19RAB9ASMN1; SMN2CYP3A4 | |
| SCHEMBL3305547 | 0.79 | CYP1A2 (0.49) | CYP1A2CYP2C19RAB9ASMN1; SMN2CYP3A4 | |
| SCHEMBL1820891 | 0.77 | CYP1A2 (0.51) | CYP1A2CYP2C19RAB9ASMN1; SMN2CYP3A4 | |
| SCHEMBL11478440 | 0.77 | SMN1; SMN2 (0.56) | CYP1A2CYP2C19RAB9ASMN1; SMN2CYP3A4 | |
| Hydrochloric Acid SCHEMBL11471926 | 0.76 | SMN1; SMN2 (0.55) | CYP1A2CYP2C19RAB9ASMN1; SMN2CYP3A4 | |
| SCHEMBL1143383 | 0.76 | CYP1A2 (0.62) | CYP1A2CYP2C19RAB9ASMN1; SMN2CYP3A4 | |
| SCHEMBL6761636 | 0.76 | F10 (0.56) | F10 | |
| Hydrochloric Acid SCHEMBL11473767 | 0.75 | CYP1A2 (0.61) | CYP1A2CYP2C19RAB9ASMN1; SMN2CYP3A4 | |
| SCHEMBL21874531 | 0.75 | CYP1A2 (0.56) | CYP1A2CYP2C19RAB9ASMN1; SMN2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040116399-A1 | Inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. | 2004-06-17 | — | — | US | disclosed |
| US-6632815-B2 | Show selectivity for factor Xa versus other proteases of coagulation or the fibrinolytic cascades | MILLENNIUM PHARMACEUTICALS, INC. | 2003-10-14 | — | — | US | disclosed |
| US-20020091116-A1 | Show selectivity for factor Xa versus other proteases of coagulation or the fibrinolytic cascades | MILLENNIUM PHARMACEUTICALS, INC. | 2002-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020091116-A1 | Show selectivity for factor Xa versus other proteases of coagulation or the fibrinolytic cascades | SERPINC1, TFPI, F2 | CYP1A2 3750/4885CYP2C19 3605/4885RAB9A 1818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.